Lineage Cell Therapeutics Inc (AMEX: LCTX) started the day on Thursday, with a price decrease of -4.95% at $1.73, before settling in for the price of $1.82 at the close. Taking a more long-term approach, LCTX posted a 52-week range of $0.37-$2.09.
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was -2.93%. Meanwhile, its Annual Earning per share during the time was -2.93%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -111.11%. This publicly-traded company’s shares outstanding now amounts to $228.36 million, simultaneously with a float of $215.49 million. The organization now has a market capitalization sitting at $395.06 million. At the time of writing, stock’s 50-day Moving Average stood at $1.5848, while the 200-day Moving Average is $0.9355.
Lineage Cell Therapeutics Inc (LCTX) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Lineage Cell Therapeutics Inc’s current insider ownership accounts for 5.64%, in contrast to 43.05% institutional ownership.
Lineage Cell Therapeutics Inc (LCTX) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.0 per share during the current fiscal year. Lineage Cell Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -111.11% and is forecasted to reach -0.07 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 1.25% through the next 5 years, which can be compared against the -2.93% growth it accomplished over the previous five years trading on the market.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Trading Performance Indicators
Let’s observe the current performance indicators for Lineage Cell Therapeutics Inc (LCTX). It’s Quick Ratio in the last reported quarter now stands at 4.08. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 36.21.
In the same vein, LCTX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.18, a figure that is expected to reach -0.03 in the next quarter, and analysts are predicting that it will be -0.07 at the market close of one year from today.
Technical Analysis of Lineage Cell Therapeutics Inc (LCTX)
If we take a close look at the recent performances of Lineage Cell Therapeutics Inc (AMEX: LCTX), its last 5-days Average volume was 2.56 million that shows progress from its year to date volume of 1.87 million. During the previous 9 days, stock’s Stochastic %D was recorded 33.14% While, its Average True Range was 46.93.
Raw Stochastic average of Lineage Cell Therapeutics Inc (LCTX) in the period of the previous 100 days is set at 71.97%, which indicates a major rise in contrast to 35.71% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.1165 that was higher than 0.0993 volatility it exhibited in the past 100-days period.
